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Abstract
Myelin of the adult central nervous system (CNS) is one of the major sources of inhibitors of axon regeneration following
injury. The three known myelin-derived inhibitors (Nogo, MAG, and OMgp) bind with high affinity to the Nogo-66 receptor
(NgR) on axons and limit neurite outgrowth. Here we show that RNA aptamers can be generated that bind with high affinity
to NgR, compete with myelin-derived inhibitors for binding to NgR, and promote axon elongation of neurons in vitro
even in the presence of these inhibitors. Aptamers may have key advantages over protein antagonists, including low
immunogenicity and the possibility of ready modification during chemical synthesis for stability, signaling, or
immobilization. This first demonstration that aptamers can directly influence neuronal function suggests that aptamers
may prove useful for not only healing spinal cord and other neuronal damage, but may be more generally useful as
neuromodulators.
Citation: Wang Y, Khaing ZZ, Li N, Hall B, Schmidt CE, et al. (2010) Aptamer Antagonists of Myelin-Derived Inhibitors Promote Axon Growth. PLoS ONE 5(3):
e9726. doi:10.1371/journal.pone.0009726
Editor: Petri Kursula, University of Oulu, Germany
Received July 9, 2009; Accepted February 22, 2010; Published March 16, 2010
Copyright:  2010 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded in part by the National Science Foundation, the Howard Hughes Medical Institute through the Freshman Research Initiative, the
Texas Institute for Drug and Diagnostics Development, the Gillson Longenbaugh Foundation, and by the Welch Foundation (F-1654). The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: andy.ellington@mail.utexas.edu
Introduction
Patients with spinal cord injury suffer from permanent
functional deficits and paralysis due to the limited capacity of
axons to regenerate. Unlike their counterparts in the peripheral
nervous system (PNS), damaged axons in the central nervous
system (CNS) do not regenerate spontaneously because of an
inhibitory environment. Studies have shown that CNS myelin is a
major source of inhibition to axon regeneration [1–3]. Trauma to
the CNS can result in major disruptions in white matter tracts,
including breakdown of myelin sheaths. Products of this myelin
breakdown come in contact with the surfaces of severed axons and
inhibit regeneration. The three known major myelin-derived
inhibitors are Nogo-A, myelin-associated glycoprotein (MAG), and
oligodendrocyte myelin glycoprotein (OMgp). All three bind with
high affinity to the Nogo-66 receptor (NgR) on axonal surfaces [1–
3]. Enzymatic cleavage of NgR confirms this effect, in that it
increases axon regeneration [1]. It was recently shown that
phosphorylation of NgR by casein kinase II also inhibits binding of
the myelin-associated proteins and promotes regeneration [4].
Because NgR is a GPI-linked receptor and lacks an intracellular
signaling domain, it relies on the transmembrane co-receptor, p75,
to transduce the inhibitory signal. The final step in the signaling
pathway is the activation of RhoA, a small GTPase that regulates
actin polymerization and inhibits axonal elongation in its active
form. Nogo-A, MAG, and OMgp activate RhoA through the
NgR/p75 receptor complex, and this NgR/p75-complex/RhoA
pathway is postulated to be responsible for the inhibitory signals
that prevent axon regeneration [5].
Recent pharmacological methods to overcome CNS myelin
inhibition involved the use of an anti-Nogo antibody [6,7], RhoA
inhibitors [8,9], a NgR antagonist peptide [10], and soluble NgR
[11].
There are potential problems with these inhibitors as therapeu-
tic agents. For example, the direct blockade of RhoA with an
inhibitor may disrupt other, crucial Rho-related cellular activities.
In contrast, the anti-Nogo antibodies are only specific for Nogo
and do not disrupt MAG or OMgp action. Because of this, it may
be useful to identify high affinity inhibitors that more generally
interact with the surface of NgR.
Aptamers are single-stranded oligonucleotides that fold into
unique three-dimensional structures, allowing them to bind to
protein targets with high affinity and specificity. They are an
alternative to therapeutic antibodies but can be chemically
synthesized in a cell-free system. Furthermore, aptamers have a
number of advantages over peptide and protein antagonists,
including their relatively low cost of production, ease of GMP
manufacture, and the simplicity with which they can be modified
for stability, signaling, and immobilization [12–15]. Studies have
shown that aptamers have no or low immunogenicity, and are
generally non-toxic [16,17], which is a great advantage in
comparison to antibodies given the length of treatment period
required for spinal cord injuries. Because of this aptamers are
seeing increasing clinical use. Macugen, a pegylated 2-fluoro
pyrimidine RNA aptamer and a potent inhibitor of the angiogenic
regulatory protein, VEGF(165) [18–20], was approved by the
FDA for treatment of neovascular age-related macular degener-
ation in 2004.
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disorders, such as Alzheimer’s [21,22], multiple sclerosis [23,24],
and myasthenia gravis [25,26]. For example, an aptamer was
selected against the 40 amino-acid beta-amyloid peptide and was
shown to bind fibrils consisting of the peptide [22]. But no
functional data regarding fibril dissociation or reduction has been
reported. Similarly, aptamers have been used to target myasthenia
gravis, which is a neuromuscular disorder resulting from antibody-
mediated autoimmune response to the nicotinic acetylcholine
receptor (AChR). A 29-amino-modified aptamer was isolated
against Mab198, a monoclonal antibody that recognizes the major
immunogenic epitope on human AchR [25]. The aptamer
protected AChR from antoantibodies found in patients with
myasthenia gravis. A later selection yielded a 29-fluoropyrimidine-
modified aptamer, which offered even greater protection [26].
However, in these instances aptamers have primarily been used to
treat disorders, rather than to modulate normal neuronal function.
Here, we selected RNA aptamers that bind to NgR with high
specificity and affinity. Most importantly, these aptamers were
shown to compete with Nogo, MAG, and OMgp for binding to
NgR. Neurite outgrowth assays demonstrated that these aptamers
can reverse the effect of these inhibitors in vitro. These are the first
aptamers to modulate neuronal growth.
Results
Selection of Anti-NgR aptamers
A RNA pool containing 50 randomized positions (R50) flanked
by two constant, primer-binding regions was used as a starting
point for selection. The protein target was a fusion of the
extracellular domain of rat NgR and the constant region of human
IgG. In each round of selection, RNA-binding species were
separated from weak or non-binding species by passing the
protein:nucleic acid complexes through a modified nitrocellulose
filter. Captured species were amplified via reverse transcription
and PCR. Negative selections were carried out to remove
aptamers that bound species (the filter, IgG, and BSA) other than
the target. Iterative rounds of selection and amplification were
performed until the target-binding aptamers dominated the
selected population.
Binding progressively increased and saturated at round 10. The
selected population showed good specificity for NgR (36% RNA
binding at 1 mM protein concentration), with little binding to BSA,
IgG, or the filter (,1% RNA binding at 1 mM protein
concentration). The population was cloned and sequenced, and
a best-binding, dominant aptamer (Clone 6), was identified. The
Kd of Clone 6 was estimated to be around several hundred nM
using a three point binding assay (data not shown), which we
deemed not sufficiently low to compete with endogenous
inhibitors. To further improve affinity, additional variants were
selected from a partially randomized pool based on Clone 6 that
contained 70% wild-type and 30% non-wild type nucleotides. This
level of mutagenesis should allow the accumulation of not only
additional functional residues, but also changes in or additions to
base-paired structures. In addition, a new selection was carried out
with a slightly longer pool (N62) in order to identify aptamers that
might cover larger swaths of the NgR surface and thereby prevent
binding of multiple inhibitors.
At the conclusion of both selections, 56 clones were sequenced:
28 from the Clone 6 doped re-selection, and 28 from the N62
selection. As expected, the best ligands for NgR were present
multiple times in the selected populations (Figure S1). However,
no strong consensus sequences or motifs emerged from the
selections. The diversity of aptamer sequences could mean that the
selected aptamers interact in several different ways with NgR, a
result that is consistent with the fact that very different myelin-
derived inhibitors all bind to NgR.
The aptamers (Clones 40, 79, 83, 110, and 152) that were used
for in vitro studies were chosen based both on affinity and on their
ability to bind to non-overlapping sites. The identified aptamers
bound NgR with Kd values from 21 to 61 nM (Table 1; Figure
S2). Competition assays between aptamers were carried out in
order to determine whether they bound to the same, different, or
overlapping epitopes (Figure S3). For example, Clone 40 bound
to a similar set of sites as Clones 29 and 39, but with higher
affinity. In contrast, Clones 110 and 152 showed little ability to
compete with one another, and thus likely bound very different
epitopes. The fact that the aptamers seemed to bind to non-
overlapping sites on NgR is consistent with the selection of
multiple, different aptamers from both the original and doped
sequence selections.
Aptamers generally block inhibitor binding to NgR
The predicted protein structure of NgR includes a signal
sequence, eight central leucine-rich repeats (LRRs) flanked by a
cysteine-rich C-terminal subdomian (LRRCT) and a smaller
leucine-rich N-terminal subdomain (LRRNT) [1,27]. Studies
suggest that all three inhibitors (MAG, Nogo, and OMgp) bind
overlapping sites in the LRR repeat domains [2,28]. To determine
whether or not the aptamers could more generally interfere with
inhibitor binding, we assayed five of the best binding aptamers in
competition with Nogo, MAG, and OMgp. Remarkably,
aptamers blocked more than one inhibitor simultaneously, and a
modest diminution of aptamer binding (3–10 fold) was only seen at
the highest total inhibitor concentration (2400 nM) (Figure 1). As
might be expected, there was a direct correlation between the
affinity of the aptamers for NgR and the ability of the aptamers to
compete with inhibitors for binding. The aptamers with the lowest
Table 1. The sequences of the random regions of the aptamers tested in neurite outgrowth assays, maximum percent binding
(Bmax) in our standard assay, and dissociation constants (Kd).
Clone Sequence Bmax(%) Kd(nM)
40 ATAACACGACATCCATATGTCAGTGGTCTGTGTACTTACACGGTATTCGA 81672 5 68
79 ACTACACGAGGACCTACGACTACTACATTATGCCAACCGGTCTTGCTTCGACACAGATACCTC 85686 0 616
83 TTGCACAAGATACGGCTACCTGTATGCGGCAATCGGCATTAAATCTATCTAAGCCAGCAGTAAC 65632 1 64
110 ATAACACGACATCCATATGTCAGTGGTCTGTGTACGTACACGGTATTCGC 95685 0 613
152 GGCGATAGTTTCTATAGCAAGGTACAGCATTCTCTCTCCCTATAGAACCAATCCAGTACTAGC 84686 1 616
doi:10.1371/journal.pone.0009726.t001
Anti-NgR Aptamers Grow Axons
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decrease in binding in the presence of the inhibitors.
Aptamers localize to NgR-expressing neuronal and non-
neuronal cell surfaces
Microscopy confirmed the binding of fluorescently-labeled
aptamers to dissociated dorsal root ganglia (DRG), which have
previously been shown to express NgR on their surfaces [29]. After
staining with a neuron-specific anti-beta III tubulin antibody, we
found NgR expression in non-neuronal cell types in addition to
DRG neurons (data not shown). To determine the nature of these
non-neuronal, NgR-expressing cells, we stained the culture with
an anti-S100 antibody, which identifies Schwann cells. The co-
localization of the anti-NgR aptamers with the anti-S100 antibody
suggested that NgR is expressed on Schwann cells. This discovery
was further confirmed with an anti-NgR antibody, which again
bound both neurons and Schwann cells (Figure 2). There was
little to no binding to a cell line (A431) that lacked NgR, although
the 431 cells were readily stained with a positive control, an anti-
EGFR aptamer (Figure S4).
Disinhibition of neurite outgrowth
To the extent that aptamers can compete with the inhibitors
Nogo, MAG, and OMgp for binding to NgR, they were likely to
show one of two biological effects: potentiation of neurite
outgrowth (due to inhibition of the inhibitors) or inhibition of
neurite outgrowth (due to mimicking of the inhibitors). To choose
between these hypotheses, dorsal root ganglia (DRG) were isolated
from P1-P3 rats and dissociated into single cells. The primary
cultures included neurons and non-neuronal cells, such as
Schwann cells. Throughout the study, the mitotic inhibitor 5-
fluoro-29-deoxyuridine (5-FDU) was added to arrest proliferation
of non-neuronal cells.
In accordance with previous studies [28,30–33], the three
myelin-derived inhibitors reduced axon elongation, as measured
by the length of neurites formed in culture (p,0.0001).
Approximately 200–500 cells were measured for each condition
in triplicate (Figure 3). In contrast, the addition of aptamers
increased growth significantly relative to the inhibitors-only
control (p,0.001). Recovery of growth ranged 80–91% relative
to the no-inhibitor control, almost a two-fold increase from full
inhibition. Clone 83, the aptamer with the lowest binding
constant, resulted in the highest reversal of inhibition among the
aptamers, although at the concentrations assayed all of the
aptamers showed similar effects on neurite outgrowth. In contrast,
the negative control, random RNA molecules at the same
concentration, did not affect axon elongation. Because all RNA
samples were prepared at the same time using the same reagents
and methods, this shows that the aptamers promoted neurite
outgrowth based on their particular sequences and structures
alone.
Soluble NgR(310)ecto was used as a positive control and could
also compete with inhibitors and increase neurite outgrowth [11].
The soluble receptor at 1 mM, a concentration more than 3-fold
that of the inhibitors, was not as effective as the aptamers in
reversing the inhibition. A further disadvantage of the soluble
NgR(310)ecto is that it only sequesters inhibitors in a one-to-one
ratio whereas one aptamer could compete with the binding of
multiple inhibitors (Figure S5).
Discussion
The myelin-associated inhibition of axon regeneration presents
a major barrier to recovery from central nervous system injury.
Here, we have shown that RNA aptamers can be selected to bind
the Nogo-66 receptor (NgR) and compete with myelin-derived
inhibitors of axon regeneration for binding to the receptor.
Furthermore, neurite outgrowth assays demonstrated that these
aptamers can reverse the effect of these inhibitors in vitro.
The selected aptamers have binding affinities (21 to 61 nM)
lower or comparable to other protein antagonists. The anti-Nogo
Figure 1. Competition assay between aptamers and myelin-derived inhibitors. The three myelin-derived inhibitors (Nogo, MAG, OMgp) at
excess concentrations (200 or 800 nM for each of the three inhibitors, implying 600 and 2400 nM total inhibitor concentrations) reduced aptamer
(5 nM) binding to NgR (50 nM) in a standard assay. Results were normalized to the aptamer alone controls. Binding data is the average of two
determinations.
doi:10.1371/journal.pone.0009726.g001
Anti-NgR Aptamers Grow Axons
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the wild-type and engineered II.1.8 mutant, respectively [34];
while the NgR antagonist peptide NEP 1–40 shows half-
maximum inhibition at 50 nM [10]. Furthermore, in contrast
to existing antagonists, these aptamers blocked more than one
inhibitor simultaneously and could more generally interfere with
inhibitor binding. The NEP1–40 peptide significantly, but only
partially, blocks myelin inhibition [10]. This is because the
peptide antagonist only blocks Nogo-66 mediated activity but not
that of MAG [35,36]. Similarly, a disadvantage of the soluble
NgR(310)ecto is that it only sequesters inhibitors in a one-to-one
ratio whereas one aptamer could compete with the binding of
multiple inhibitors. Given that all three inhibitors (MAG, Nogo,
and OMgp) bind overlapping sites in the leucine rich repeat
(LRR) domains of NgR [2,3], molecules that generally interfere
with the binding of all three inhibitors would have the best
efficacy.
Using these aptamers as detection tools, we unexpectedly found
the expression of NgR on Schwann cells. The localization of both
the anti-NgR aptamers and antibody to Schwann cell surface led
us to speculate the role of NgR on these cells. Schwann cells form
the basis for nerve regeneration and repair in the PNS. Upon
losing contact with axons such as following injury, mature
Schwann cells undergo developmental regression and proliferation
to provide an environment inductive to axonal re-growth [37].
However, Schwann cells were previously reported not to express
either Nogo or its receptor via in situ hybridization [38]. The
difference between the previous study and our own findings might
be the age-dependent expression of NgR in Schwann cells. The rat
pups used in our experiments were newborns; whereas the mice
pups used in the previous study were postnatal day 7. NgR
expression might be downregulated as the animals reach
adulthood, as previously observed in the spinal cord for humans
and mice [38].
Studies have shown that the lack of regeneration in the CNS
results from a hostile environment. For example, injured CNS
axons can extend over long distances in the presence of a
peripheral nerve graft [39]. Given that PNS is significantly more
permissive for growth relative to the CNS and that Schwann cells
have a role in inducing axonal re-growth in the PNS, it is possible
that these surface receptors act as competitive binders for myelin-
derived inhibitors that might otherwise come in contact with
growing axons. Indeed, given the larger number of Schwann cells,
it is possible that these cells act as a ‘buffer’ for the varying
amounts of myelin-derived inhibitors that may be released. It is
also interesting that these supporting cells express both NgR and
myelin-proteins, such as MAG, but not Nogo and OMgp [40].
This suggests an interesting scenario in which early Schwann cells
can express both inhibitors of neurite growth and proteins that will
bind the inhibitors, allowing the concentrations of these inhibitors
to be very finely tuned in order to fine-tune neurite outgrowth over
time.
Figure 2. NgR expression in dorsal root ganglia and Schwann cells. DRG neurons in primary cultures were labeled using an anti-beta III
tubulin antibody (green; columns A, C). Schwann cells were labeled using an anti-S100 antibody (green; columns B, D). Binding of a biotinylated anti-
NgR aptamer (Clone 40) was detected with PE-labeled streptavidin (red; A, B). Binding of a biotinylated anti-NgR antibody was also detected with PE-
labeled streptavidin (red; C, D). Yellow in the overlay indicates the overlap of green and red stains. Arrows in Column A indicate the position of a
growth cone in a DRG neuron, and the overlay suggests localized expression of NgR. Scale bars: 25 mm (A); 50 mm (B-D).
doi:10.1371/journal.pone.0009726.g002
Anti-NgR Aptamers Grow Axons
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to overcome the myelin-associated inhibition to regeneration. The
aptamers prove to be better growth promoters than other, protein-
based compounds that have previously been assayed, and may
offer a novel therapeutic modality for neural regeneration. That
said, the aptamers did not compete with peptides as well as their
affinity constants might have indicated. The selection of aptamers
that include modified nucleotides would significantly improve the
ability to compete in serum and eventually in animal models, and
we are now pursuing these studies. Most importantly, this work
shows that aptamers can be valuable tools not only in
neuopathologies, but also in modulating and redefining normal
neuronal architectures.
Other than its function in restricting neurite outgrowth, NgR
also has an apparent role in preventing NGF-stimulated
p75NTR-dependent motor neuron death as recently shown
[41]. Peptides derived from one of its ligands, Nogo, exert
neuroprotective effects through NgR binding. It would be
interesting to study the effect of these aptamers to determine
whether or not they can both prevent motor neuron death and
promote their axonal elongation.
Materials and Methods
In Vitro Selection
Aptamers against NgR were generated by in vitro selection,
starting from synthetic DNA libraries. For the R50 pool, an
oligonucleotide containing a 50-nucleotide random region (N50)
flanked by constant regions were synthesized: 59-G A TAATACG-
ACTCACTATAGGGTTTACCTAGGTGTAGATGCT-N50-A
AGTGACGTCTGAACTGCTTCGAA-39. The underlined por-
tion is the T7 RNA polymerase promoter region. Similarly, the
N62 pool consisted of a 62-nucleotide (N62) region flanked by a
different pair of primers: 59 -G A TAATACGACTCACTATAG-
GCGCTCCGACCTTAGTCTCTG-N62-GAACCGTGTAGC-
ACAGCAGA - 3.9 Following in vitro transcription by T7 RNA
polymerase (Epicenter Technologies, Madison, WI), the derived
RNA library was purified on an 8% denaturing polyacrylamide
gel, then eluted and precipitated. In order to eliminate aptamers
from the population that bound to either the filter or the Fc region,
an initial negative selection was carried out. The RNA population
(,200 pmol, 10
14 sequences) was incubated with 200 pmol of
recombinant human IgG Fc (R&D Systems, Minneapolis, MN)
Figure 3. Neurite outgrowth assays with dorsal root ganglia. The myelin-derived inhibitors (Nogo, MAG, and OMgp) were added at 300 nM
total (100 nM each). Aptamers (Clones 40, 79, 83, 110, and 152) were added at a concentration of 10 mM. (A) Visualization of neurite lengths. DRGs
were stained with a neuron-specific anti-beta III tubulin antibody. The pictures shown are representative examples. Scale bar, 200 mm. (B) Average
neurite lengths. Data was collected over 200–500 neurons per condition, and means + standard deviations are reported. Binding was normalized to a
buffer alone control.
doi:10.1371/journal.pone.0009726.g003
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separated from unbound on a modified cellulose filter (Millipore,
Bedford, MA). The molecules that passed through the filter were
collected and then incubated with recombinant rat Nogo
receptor/Fc chimera (R&D Systems, Minneapolis, MN) in
selection buffer (PBS, pH 7.4, 3 mM MgCl2) for 30 mins. Since
the rat sequence (SwissProt entry Q99M75) of the immunogen
peptide and the mouse sequence (SwissProt entry Q99PI8) are
100% identical, the difference in species does not present a
problem for later neurite outgrowth assays using rat neurons.
Separation through a modified cellulose filter again trapped
proteins and bound RNAs. After washing with 600 mL Selection
Buffer, RNA molecules were eluted from the filter in 200 nM
NaCl, 50 mM Tris-HCl, pH 7.4, 10 mM DTT, and 6 mM
MgCl2, and amplified by reverse transcription and the polymerase
chain reaction (Invitrogen, Carlsbad, CA). An aliquot of the
amplified DNA template (,1 mg or 20 pmol, roughly one-sixth of
total amount of amplicon produced) was used in a transcription
reaction to generate an RNA pool for the subsequent round of
selection. Iterative rounds of selection and amplification were
performed until the target-binding aptamers dominated the library
population. In later rounds, the protein: RNA ratio, the MgCl2
concentration, and the incubation time during the binding
reaction were altered to increase stringency. The protein:RNA
ration was 1:1 for the first two rounds, and 1:2 for subsequent
rounds (protein was kept constant at 200 pmol, and RNA was
varied from 200 to 400 pmol). The MgCl2 concentration was
5 mM for the first three rounds and 3 mM for the subsequent
rounds. The incubation time was 30 mins for the first three rounds
and 20 mins for later rounds. Following sequencing, the MEME
server [http://meme.sdsc.edu] was used to find potential sequence
motifs.
Selections to optimize Clone 6, the dominant aptamer from the
initial selection (Figure S1), were performed in a similar manner.
The sequence for the partially randomized pool based on Clone 6
was 59GGGTTTACCTAGGTGTAGATGCTCTCTCTATTTC-
ATTCGTAGGCTATTGGTGCCGCAAATACTAGCTTTACGAAAG-
TGACGTCTGAACTGCTTCGAAAA - 39, where the italicized
residues indicate positions that were synthesized at 70% wild-type
and 30% non-wild-type nucleotides.
Binding Assays
The selected population was characterized for binding to NgR
using a filter-binding assay similar to that used for the selection.
The aptamers were radioactively labeled in a transcription
reaction using [a-
32P]ATP (3000 ci/mmol, 10 mCi/ml, Perkin
Elmer, Waltham, MA). The labeled RNA was then incubated with
12.5, 18.75, 25, 50, 75, 150, 300, and 500 nM of the target protein
(NgR/FC chimera). To separate the RNA bound to protein from
free RNA, the reaction was passed through a nitrocellulose (top)
then a nylon (bottom) filter (Schleicher & Schuell, Keene, NH) on
a vacuum manifold. The nitrocellulose captured the RNA:protein
complexes, while the nylon captured free RNA. After washing
with Selection Buffer (600 mL), the filters were dried and exposed
to a PhosphorImager plate (GE Healthcare, Piscataway, NJ) to
quantitiate the amount of retained radioactivity. The fraction of a
given RNA (population or aptamer) that bound the target proteins
was calculated by comparing the counts retained on the filter with
the total number of counts in the original RNA. Binding to IgG
and BSA were assayed similarly. The maximum binding (Bmax)
and dissociation constants (Kd) were fit using the program
SigmaPlot (Chicago, IL). The Kd curves were plotted in SigmaPlot
according to the following equation:
RNA Bound ~
Bmax Protein ½ 
Kd z Protein ½ 
:
Competition Binding Assays
Competition between aptamers and myelin-derived inhibitors
was assayed by measuring the reduction in aptamer binding in
the presence of the inhibitors. The aptamers were again
radioactively labeled during transcription as described above.
The NgR/Fc chimera (50 nM) was incubated with Nogo, MAG,
and OMgp (R&D Systems, Minneapolis, MN, each at 200 nM or
800 nM) for 5 mins. Aptamers were then introduced and
incubated with the mixture for 20 mins at 37uC. The binding
reaction was passed through filters on a vacuum manifold, and
the filters were washed and quantified as described in the binding
assays above. The fraction of RNA bound was measured.
Decreases in aptamer binding due to the formation of inhibitor-
NgR complexes were determined in comparison with an aptamer
alone control.
Neurite Outgrowth Assays
Dorsal root ganglia (DRG) were removed from P1-P3 rats and
trimmed to remove axons for accurate measurements of re-
growth in RPMI (Sigma-Aldrich, St. Louis, MO). DRGs were
dissociated into single cells by incubation with 0.25% collagenase
type I (Sigma-Aldrich) at 37uC for 30 mins and 0.025% trypsin
(Sigma-Aldrich, St. Louis, MO) for 37uC for 10 mins. Dulbecco’s
Modified Eagle’s Medium (Sigma-Aldrich) with 10% fetal bovine
serum (Hyclone, Logan, UT) and 1% penicillin-streptomycin
(Sigma-Aldrich) was added to dissociated cells, and the cells were
plated in 24-well plates coated with 50 mgp o l y - L - l y s i n e / m L
(Sigma-Aldrich, St. Louis, MO) and 10 mg laminin/mL (Trevi-
gen, Gaithersburg, MD) at a density of 50,000 cells/well. At the
time of plating, 30 nM of 5-fluoro-29-deoxyuridine (Sigma-
Aldrich) was added to arrest proliferation of non-neuronal cell
types. The three myelin-derived inhibitors (each at a final
concentration 100 nM), RNAse inhibitors at 1.6 Units/ml
(Ambion, Austin, TX), and a given RNA (final concentration
10 mM) were added an hour after plating (to minimize
interference with cell adherence). After 24 hours of incubation,
the cells were fixed in 4% paraformaldehyde, immunostained
with a neuron-specific anti-b-tubulin III antibody (Abcam,
Cambridge, MA) and an Alexa Fluor 488-labeled goat anti-
rabbit IgG (Invitrogen, Carlsbad, CA) as the secondary antibody.
To assay the impact of compounds on neurite outgrowth, the
lengths of individual immunostained neurites were measured.
The cell density and growth time were optimized to ensure that
neurons grew in relative isolation from each other and that
neurites from nearby cells did not fasciculate. An inverted
fluorescence microscope (IX-70, Olympus) was used to visualize
the cells, and images from the microscope were acquired using a
color CCD video camera (Optronics Magna-Fire, model S60800).
Quantification of neurite outgrowth was performed over a sample
of 200–500 neurons per condition using Leica QWIN Image
Analysis software (Leica Microsystems, Bannockburn, IL). Gray
image processing was first used to identify all anti-b-tubulin III-
stained neurons. Cell bodies were subsequently removed using
BINARY EDIT functions. The curve lengths (defined as the
length of the longest side of a rectangle having the same area and
perimeter as the measured feature) of the remaining neurites on
200–500 neurons were measured and averaged. The significance
of the collected data was assessed using a pairwise t-test with
Bonferroni correction (Table S1).
Anti-NgR Aptamers Grow Axons
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To better label the aptamers, a 39 extension was added by PCR.
The extensions were 59 CTGGTCATGGCGGGCATTTAATTC-
TTCGAAGCAGTTCAGACGTCACTT 39 for the R50 pool;
and 59 CTGGTCATGGCGGGCATTTAATTCTCTGCTGTGC-
TACACGGTTC 39 for the N62 pool. The italicized portions
indicate regions of complementarity to a biotinylated oligonucle-
otide. RNAs (1 mM) transcribed from the extended templates were
purified and hybridized to the biotinylated oligonucleotide (59
GAATTAAATGCCCGCCATGACCAG 39)( 1mM) by heating
to 70uC for 3 mins and cooling to 25uC. The RNA:DNA hybrid
was further incubated with streptavidin:phycoerythrin (PE) (1 uM)
to generate fluorescent complexes. Dissociated DRGs were
prepared as described above. The entire aptamer:biotinylated
oligonucleotide:streptavidin:PE complex was incubated with the
dissociated DRG culture for 30 mins in the presence of RNAse
inhibitors at 1.6 units/ml (Ambion, Austin, TX). The DRGs were
then washed 3 times with selection buffer (PBS + 3 mM MgCl2),
fixed in 4% paraformaldehyde, and immunostained with a
neuron-specific anti-b-tubulin III antibody (Abcam, Cambridge,
MA) or an anti-S100 antibody (Abcam, Cambridge, MA) with an
Alexa Fluor 488-labeled goat anti-rabbit IgG (Invitrogen,
Carlsbad, CA) as the secondary antibody. Staining with a
biotinylated anti-NgR antibody (R&D Systems, Minneapolis,
MN) was performed similarly, except that the antibody was
conjugated to streptavidin:PE. Fluorescence images were collected
using a Leica SP2 AOBS confocal microscope. The brightness and
contrast of images were enhanced in Adobe Photoshop (Adobe,
San Jose, CA) to optimize visualization.
Supporting Information
Figure S1 Aptamer sequences. The random regions of aptamers
from the R50 doped selection (A) and the N62 selection (B) are
shown. Out of the 58 clones sequenced, there were 23 distinct
sequences. Several 5-bp long motifs (colored) appeared in multiple
aptamers. (*) indicates the highest-affinity binders based on a single
point binding assay, many of which appeared multiple times in the
cloned population. These high-affinity binders were competed
with one another to identify aptamers that bound to distinct
regions on NgR (Figure S3). ({) indicates the highest affinity
aptamers that bound to relatively non-overlapping regions on NgR
and that were further tested in neurite outgrowth assays (see also
Table 1).
Found at: doi:10.1371/journal.pone.0009726.s001 (0.34 MB TIF)
Figure S2 Determination of aptamer binding constants. The
protein concentrations were 12.5, 18.75, 25, 50, 75, 150, 300, and
500 nM. The RNA concentration was 0.5 nM. Binding curves
were fit using the program SigmaPlot to yield Kd and Bmax
values.
Found at: doi:10.1371/journal.pone.0009726.s002 (0.01 MB TIF)
Figure S3 Competition between aptamers for binding to NgR.
The highest affinity species from the R50 doped re-selection (C29,
C37, C39, C40, and C110) and the N62 selection (C79, C83, and
C152) (Figure S1) were chosen to compete with one another in
order to identify binders to non-overlapping regions on NgR.
Black denotes the binding of the radiolabeled aptamer (10 nM) to
NgR (100 nM), without competition. Binding of a radiolabeled
aptamer in the presence of a cold aptamer competitor (500 nM; or
a 50:1 ratio of cold:radiolabeled aptamer) is shown with a different
color. Based on these results, C29 and C39 have similar
competition profiles to C40, but bound with lower apparent
affinity. Therefore, C29 and C39 were not further investigated.
Likewise, C37 bound similarly to C152 but with lower affinity.
Found at: doi:10.1371/journal.pone.0009726.s003 (5.82 MB TIF)
Figure S4 Anti-NgR aptamers are specific for neuronal cell
lines. Biotinylated aptamers and antibodies were labeled using
Alexa568 streptavidin. The human epithelial carcinoma tissue
culture cell line A431 expresses EGFR (epidermal growth factor
receptor) but not NgR. Thus an anti-NgR aptamer (Clone 40) and
an anti-NgR antibody showed little binding to these cells (no
bright spots, top two panels) relative to an anti-EGFR aptamer
(bottom panel).
Found at: doi:10.1371/journal.pone.0009726.s004 (5.82 MB TIF)
Figure S5 Competition between aptamers and individual
myelin-derived inhibitors. The three myelin-derived inhibitors
(Nogo, MAG, OMgp) at excess concentrations (800 nM each)
were incubated with the aptamer (10 nM) and NgR (50 nM) in a
standard binding assay. MAG and OMgp generally reduce
aptamer binding. This suggests these inhibitors and aptamers
bind to overlapping or identical sites on NgR. It should be noted
that even though Nogo does not appear to compete with the
aptamers, it also does not appear to be effective in reducing
aptamer-stimulated neurite outgrowth (Figure 3), suggesting it may
bind more weakly than aptamers to NgR.
Found at: doi:10.1371/journal.pone.0009726.s005 (5.82 MB TIF)
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